The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05692596

Enrollment

317

Registered

2023-01-20

Start date

2022-10-06

Completion date

2027-07-01

Last updated

2026-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ataxia Telangiectasia, BRCA Mutation, Chronic Pancreatitis, Familial Atypical Multiple Mole-Melanoma, FAP, Fatty Pancreas, Genetic Pancreatic Cancer, Genetic Pancreatitis, Lynch Syndrome, PALB2 Gene Mutation, Pancreatic Cyst, Pancreatic Ductal Adenocarcinoma, Peutz-Jeghers Syndrome

Keywords

pancreas, database

Brief summary

The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.

Interventions

OTHERData collection

Investigators will compile data typically collected clinically. This data will include demographics, cancer screening procedures, cancer diagnosis and staging, chemotherapy, immunotherapy, radiation therapy, surgery, comorbidities, medication use, lifestyle and other cancer risk factors, quality of life, vital status, and molecular data generated from specimens collected clinically.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* 18 years of age or older * Moffitt Cancer Center patients presenting with a pancreatic cyst, and/or inherited syndrome that predisposes them to pancreatic ductal adenocarcinoma (PDAC) * Moffitt Cancer Center patients undergoing evaluation for localized/early stage PDAC. * Moffitt Cancer Center patients with a combination of PDAC risk factors such as a history of chronic or new-onset diabetes, pancreatitis, obesity, tobacco exposure, toxin exposure and/or heavy alcohol consumption.

Design outcomes

Primary

Measure	Time frame	Description
Database creation	24 months	A centralized, real-time, queryable and secure database will be developed that will integrate data on Moffitt patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), pancreatic cystic lesions (benign, pre-cancerous and malignant), or an inherited PDAC susceptibility.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORShaffer Mok, MD, MBS

Moffitt Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 16, 2026